NZ740157A - Methods of improving myocardial performance in fontan patients using udenafil compositions - Google Patents
Methods of improving myocardial performance in fontan patients using udenafil compositionsInfo
- Publication number
- NZ740157A NZ740157A NZ740157A NZ74015715A NZ740157A NZ 740157 A NZ740157 A NZ 740157A NZ 740157 A NZ740157 A NZ 740157A NZ 74015715 A NZ74015715 A NZ 74015715A NZ 740157 A NZ740157 A NZ 740157A
- Authority
- NZ
- New Zealand
- Prior art keywords
- udenafil
- methods
- fontan
- patients
- myocardial performance
- Prior art date
Links
- IYFNEFQTYQPVOC-UHFFFAOYSA-N udenafil Chemical compound C1=C(C=2NC=3C(CCC)=NN(C)C=3C(=O)N=2)C(OCCC)=CC=C1S(=O)(=O)NCCC1CCCN1C IYFNEFQTYQPVOC-UHFFFAOYSA-N 0.000 title abstract 3
- 229960000438 udenafil Drugs 0.000 title abstract 3
- 239000000203 mixture Substances 0.000 title 1
- 230000002107 myocardial effect Effects 0.000 title 1
- 230000002411 adverse Effects 0.000 abstract 1
- QVGXLLKOCUKJST-UHFFFAOYSA-N atomic oxygen Chemical compound [O] QVGXLLKOCUKJST-UHFFFAOYSA-N 0.000 abstract 1
- 230000007423 decrease Effects 0.000 abstract 1
- 230000004217 heart function Effects 0.000 abstract 1
- 238000005259 measurement Methods 0.000 abstract 1
- 229910052760 oxygen Inorganic materials 0.000 abstract 1
- 239000001301 oxygen Substances 0.000 abstract 1
- 150000003839 salts Chemical class 0.000 abstract 1
Landscapes
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
Abstract
The present invention relates generally to the field of using udenafil or a pharmaceutically acceptable salt thereof in patients who have undergone the Fontan operation. Udenafil is administered to patients whose exercise capacity is adversely affected due to a decline in heart function after Fontan palliation, with a total daily dose of 125 mg to 175 mg. Improvement of exercise capacity is determined by maximum oxygen uptake at maximum exercise output (VO2 measurement).
Priority Applications (2)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
NZ765796A NZ765796B2 (en) | 2015-06-30 | Methods of improving myocardial performance in fontan patients using udenafil compositions | |
NZ765800A NZ765800A (en) | 2014-08-12 | 2015-06-30 | Methods of improving myocardial performance in fontan patients using udenafil compositions |
Applications Claiming Priority (3)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
US201462036506P | 2014-08-12 | 2014-08-12 | |
US201562186132P | 2015-06-29 | 2015-06-29 | |
NZ72765315 | 2015-06-30 |
Publications (2)
Publication Number | Publication Date |
---|---|
NZ740157A true NZ740157A (en) | 2023-09-29 |
NZ740157B2 NZ740157B2 (en) | 2024-01-04 |
Family
ID=
Similar Documents
Publication | Publication Date | Title |
---|---|---|
PH12017501321A1 (en) | Oral care compositions and methods of use | |
NZ735575A (en) | Polycyclic-carbamoylpyridone compounds and their pharmaceutical use | |
MX2016010213A (en) | Novel pharmaceutical formulations. | |
EA201692280A1 (en) | CONNECTIONS FOR THE TREATMENT OF SPINAL MUSCULAR ATROPHY | |
NZ732391A (en) | Polycyclic-carbamoylpyridone compounds and their pharmaceutical use | |
MY200278A (en) | Methods of improving exercise capacity in fontan patients using udenafil compositions | |
PH12014502217A1 (en) | Methods for improving diaphragm function | |
PH12015501375B1 (en) | Stable metal ion containing compositions | |
MX366368B (en) | Prebiotic oral care methods using a saccharide. | |
MX2017016801A (en) | Drospirenone-based contraceptive for a female patient affected with excess weight. | |
MX2018005415A (en) | Durable dental film-forming composition and uses thereof. | |
BR112015007592A2 (en) | enalapril compositions | |
GB2523707A (en) | Novel pharmaceutical formulations and their use in the treatment of periodontal disease | |
ZA202208504B (en) | Intradialytic use of sodium nitrite | |
MX2021006488A (en) | Compositions for improving sexual function. | |
EA201890929A1 (en) | LOW DOSES OF DIPYRIDAMOL COMPOSITIONS FOR ORAL ADMINISTRATION AND THEIR USE | |
NZ740157A (en) | Methods of improving myocardial performance in fontan patients using udenafil compositions | |
MX2018002034A (en) | Prophylaxis of hypertension and cardiovascular diseases. | |
MX2017007847A (en) | Oral care composition. | |
PH12019502685A1 (en) | Use of citrulline and glutathione to increase muscle mass | |
PH12018502339B1 (en) | Oral care composition | |
GEP20156373B (en) | Use of 3-carboxy-n-ethyl-n,n-dimethylpropan-1-aminium salts in the treatment of cardiovascular disease | |
MX2017007422A (en) | Oral care composition. | |
EA201892664A1 (en) | COMPOSITION FOR CARE OF THE ORAL CAVITY | |
UA91081U (en) | Method for simulation of cataract |
Legal Events
Date | Code | Title | Description |
---|---|---|---|
PSEA | Patent sealed |